Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

MorphoSys Provides Update on the Company's Proprietary Drug Portfolio

Published: Tuesday, July 29, 2014
Last Updated: Tuesday, July 29, 2014
Bookmark and Share
Early-stage portfolio now fully Ylanthia-based, includes programs with Merck Serono as well as first anti-GPCR programs.

MorphoSys AG has provided an update on its proprietary portfolio including the clinical programs MOR208, MOR103 and MOR202. As these programs progress through clinical development, the company continually aims to strengthen its proprietary portfolio through new program starts, co-development and in-licensing agreements and potentially through M&A transactions.

"Our proprietary portfolio is progressing well and we believe that each program has a substantial therapeutic potential. Together with our partner Celgene we have decided that the next steps in our development plan for MOR202 will incorporate combinations with pomalidomide," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "With regards to MOR208, we intend to present first results from the ongoing NHL trial before year-end."

MOR208 - Priority on NHL data by the end of 2014
In a signal searching approach, MOR208 is currently being evaluated as monotherapy in phase 2 trials in NHL and B-ALL. Based on the encouraging monotherapy data in CLL, MOR208 is also being investigated in a phase 2 combination trial with lenalidomide (Revlimid®) in CLL (investigator sponsored trial at Ohio State University). MorphoSys has prioritized presenting first clinical data from the NHL trial at a major conference later this year, earlier than previously anticipated. In the trial, four different subtypes of NHL, namely follicular lymphoma (FL), mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL) and other indolent NHL types are investigated. Recruitment in B-ALL has recently been slower than originally anticipated, but enrollment is nevertheless planned to be completed by the end of 2014. For this reason, MorphoSys does not expect to present clinical data for B-ALL in 2014.

MOR103 - Results in multiple sclerosis to be published at ACTRIMS-ECTRIMS 2014
Following the successful completion of the phase 1b trial of MOR103 in multiple sclerosis an abstract covering the results of the phase 1b trial in multiple sclerosis has been accepted for the ACTRIMS-ECTRIMS meeting to take place in Boston in September. Responsibility for further development of MOR103 (GSK3196165) is now fully with GlaxoSmithKline.

MOR202 - Combinations with pomalidomide planned
MorphoSys and its collaboration partner Celgene Corporation have decided to expand the clinical development plan of MOR202 in multiple myeloma, introducing pomalidomide as a new combination partner. The MOR202 combination trials are now planned to be initiated earlier than originally anticipated. In addition, cohorts with a weekly dosing schedule, with and without dexamethasone, were added to the ongoing monotherapy trial of MOR202, which continues as planned. The expanded design of the trial will be published on As the now expanded Phase 1/2a trial will not be completed until 2015, the companies do not plan to publish any clinical data this year.

MOR106 - Joint antibody program with Galapagos in preclinical development
MorphoSys collaborates with Galapagos with the aim to discover and develop antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis. The first joint development program has recently advanced into preclinical development stage. The program named MOR106 is an antibody made using MorphoSys's next-generation antibody library Ylanthia and will be developed in inflammatory diseases.

Early Stage Programs - First anti-GPCR programs based on Ylanthia
MorphoSys has expanded its earlier stage portfolio programs from three at the beginning of the year to five at the end of the second quarter. This includes the co-development activities with Merck Serono in the immuno-oncology field. Target discovery activities have been expanded with a focus on oncology and inflammation. Several new discovery programs have been initiated with two new Ylanthia antibodies targeting G protein-coupled receptors (GPCRs).

"The impact of our next-generation antibody technology Ylanthia is increasingly visible in our portfolio. Ylanthia is ideally suited for therapeutic antibody discovery in a variety of fields including immuno-oncology, cancer stem cells and many more. The opportunity created by applying our antibody capabilities in the GPCR target space, for instance, could be enormous and we have just begun to scratch the surface by adding two new GPCR-programs to our portfolio," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys Publishes Update on MOR202 in Multiple Myeloma
First data from final 16 mg/kg dose escalation cohort and combination with immunomodulatory drugs show encouraging activity.
Thursday, September 24, 2015
MorphoSys Provides an Update on its Proprietary Development Portfolio
Lead cancer program MOR208 to be examined in numerous combination studies in hematological cancers.
Thursday, September 10, 2015
MorphoSys and Immatics Enter Strategic Alliance in Immuno-oncology
Collaboration aims to develop novel antibody-based therapies targeting tumor-associated peptides derived from intracellular proteins.
Tuesday, August 25, 2015
MorphoSys AG Reports Results for the First Six Months of 2015
Therapeutic pipeline exceeds 100 drug candidates in research & development.
Saturday, August 08, 2015
MorphoSys's Partner Heptares Initiates Proprietary Therapeutic Antibody Program
Successful discovery alliance combines two leading technologies.
Thursday, August 06, 2015
MorphoSys and G7 Therapeutics Sign Alliance
Collaboration broadens MorphoSys' capabilities to target novel antigen classes.
Thursday, August 06, 2015
MorphoSys Announces Clinical Milestone in Blood Disorders Program
Company has received milestone payment from Novartis.
Saturday, July 25, 2015
MorphoSys Presents Updated Phase 2 Clinical Results for MOR208
Matured data set shows six complete remissions with durable responses in diffuse large B-cell lymphoma and follicular lymphoma.
Thursday, June 04, 2015
MorphoSys Presents First Safety, Pharmacokinetic and Efficacy Data for MOR202
Clinical activity and long-lasting tumor control already observed at low doses.
Wednesday, June 03, 2015
MorphoSys to Present Data on Proprietary Programs at 20th Congress of EHA
Substantial data packages on lead compounds MOR202 and MOR208.
Tuesday, May 26, 2015
MorphoSys to Present Data on Proprietary Programs at ASCO Annual Meeting
Abstracts include first clinical data for MOR202.
Tuesday, May 26, 2015
MorphoSys AG Reports Results for the First Three Months of 2015
First quarter positively impacted by one-off effects relating to MOR202.
Tuesday, May 12, 2015
MorphoSys Acquires Peptide Therapeutic Company Lanthio Pharma
Acquisition adds novel candidates including Pre-IND candidate for fibrotic diseases to MorphoSys's growing proprietary portfolio.
Friday, May 08, 2015
MorphoSys to Receive Milestone Payment for Guselkumab Program
Company initiates phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody.
Tuesday, April 14, 2015
MorphoSys Nominates Three New Candidates for Supervisory Board
Company has nominated Ms. Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich.
Tuesday, March 31, 2015
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Fat Cells Originating from Bone Marrow Found in Humans
Cells could contribute to diabetes, heart disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos